GTx Files Toremifene For Prostate Cancer-Related Bone Loss
This article was originally published in The Pink Sheet Daily
Executive Summary
Biopharma is seeking a priority review for 80 mg toremifene, already marketed as Fareston at a 60 mg dose for breast cancer.